American International Group Inc. increased its stake in shares of Puma Biotechnology Inc (NASDAQ:PBYI) by 8.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,262 shares of the biopharmaceutical company’s stock after acquiring an additional 1,441 shares during the quarter. American International Group Inc. owned approximately 0.05% of Puma Biotechnology worth $2,307,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently bought and sold shares of the company. Strs Ohio bought a new position in Puma Biotechnology during the 2nd quarter worth approximately $122,000. Cubist Systematic Strategies LLC bought a new position in Puma Biotechnology during the 2nd quarter worth approximately $146,000. Sei Investments Co. bought a new position in Puma Biotechnology during the 3rd quarter worth approximately $256,000. Kazazian Asset Management LLC bought a new position in Puma Biotechnology during the 2nd quarter worth approximately $209,000. Finally, Teacher Retirement System of Texas bought a new position in Puma Biotechnology during the 2nd quarter worth approximately $211,000. Institutional investors and hedge funds own 96.05% of the company’s stock.
Shares of Puma Biotechnology Inc (PBYI) opened at $100.75 on Friday. Puma Biotechnology Inc has a 1 year low of $28.35 and a 1 year high of $136.90.
Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million during the quarter, compared to the consensus estimate of $3.78 million. During the same quarter in the prior year, the business posted ($1.11) earnings per share. equities analysts predict that Puma Biotechnology Inc will post -8.19 EPS for the current fiscal year.
In related news, SVP Richard Paul Bryce sold 15,000 shares of Puma Biotechnology stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the sale, the senior vice president now directly owns 42,239 shares in the company, valued at $5,068,680. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Charles R. Eyler sold 1,322 shares of Puma Biotechnology stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $105.46, for a total value of $139,418.12. The disclosure for this sale can be found here. 21.10% of the stock is currently owned by company insiders.
Several equities analysts recently issued reports on PBYI shares. Bank of America restated a “buy” rating and set a $135.00 price target (up from $117.00) on shares of Puma Biotechnology in a research report on Monday, October 9th. Citigroup restated a “buy” rating and set a $156.00 price target (up from $114.00) on shares of Puma Biotechnology in a research report on Thursday, October 5th. J P Morgan Chase & Co reiterated a “buy” rating and issued a $131.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, October 4th. BidaskClub upgraded Puma Biotechnology from a “hold” rating to a “buy” rating in a research report on Friday, September 8th. Finally, Stifel Nicolaus lifted their price objective on Puma Biotechnology from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $130.67.
ILLEGAL ACTIVITY WARNING: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/12/10/american-international-group-inc-buys-1441-shares-of-puma-biotechnology-inc-pbyi.html.
Puma Biotechnology Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NASDAQ:PBYI).
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.